Key Takeaways
- Pfizer yields 6.1% and NextEra Energy yields 3.0%, so $10,000 pays $610 a year in Pfizer today against $300 in NextEra.
- NextEra’s dividend grew 10.1% a year from fiscal 2020 to fiscal 2025, against 2.5% a year for Pfizer’s.
- Pfizer’s dividend took 89% of its free cash flow over the twelve months to June 2026, while NextEra paid out 61% of its fiscal 2025 normalized EPS.
- Pfizer’s 2027 guidance and Virginia’s ruling on NextEra’s Dominion Energy deal are the next things to watch.
Pfizer (PFE) raised its 2026 guidance on Nov. 3, and its stock still yields 6.1%. That’s a big check, from a dividend that ate up 89% of free cash flow over the twelve months to June 28, 2026.
NextEra Energy (NEE) yields 3.0%. But its dividend grew 10.1% a year from fiscal 2020 to fiscal 2025, against Pfizer’s 2.5%, with a much wider cushion under it. If I could hold only one of them for the next 10 years, which would I want?
| Metric | Pfizer (PFE) | NextEra Energy (NEE) |
|---|---|---|
| Dividend yield | 6.1% | 3.0% |
| Annual dividend | $1.72 | $2.49 |
| Dividend growth, fiscal 2020-2025 | 2.5% a year | 10.1% a year |
| Coverage, on its own measure | Cash dividend payout ratio: 89% (TTM to June 28, 2026) | Payout ratio of normalized EPS: 61% (fiscal 2025) |
| Net debt/EBITDA (LTM) | 1.9x | 8.1x |
| Forward P/E (NTM) | 10x | 21x |
Source: TIKR and StockAnalysis, at today’s prices.
6 safe dividend stocks paying retirees 6%+ yields
There are over 100 stocks paying 6%+ annual dividends today.
But after an extensive investment review leveraging TIKR’s proprietary data, we now believe only six of them are truly safe for retirees.
They’re all yours as part of our new investment report. Learn more about how to get access right here.
Pfizer’s big check has a thin cushion
Pfizer is replacing its COVID windfall with newer drugs. In the third quarter of 2026, products it launched or acquired grew 32% operationally, while Paxlovid fell 63%. That left revenue relatively flat at $16.6 billion, and management still raised 2026 revenue guidance to $62.0-$64.0 billion, from $60.5-$62.5 billion.
Free cash flow fell from $29.9 billion in fiscal 2021 to $9.08 billion in fiscal 2025, while dividends paid rose to $9.77 billion:

On its second-quarter call, Pfizer said it’s focused on “maintaining and over the long term, growing our dividend.” I’d take management at its word on maintaining it. Growing it looks harder with nearly all of its free cash flow already going out the door.
The main risk is patents: Pfizer names coming losses of exclusivity for IBRANCE, XTANDI and Eliquis outside the US.
NextEra’s smaller check has room to grow
Where Pfizer’s dividend leans on a business in transition, NextEra Energy’s rests on earnings that have climbed for a decade. As a utility, NextEra is judged on its payout of normalized EPS. Its dividend and EPS rose together every year from fiscal 2016 to fiscal 2025:

In fiscal 2025, the dividend was a well-covered 61% of normalized EPS ($2.27 a share against $3.71).
Management expects adjusted EPS to grow 8%+ a year through 2032, off 2025’s $3.71. Dividend growth slows, though: on Oct. 21, NextEra reiterated dividend growth of about 10% a year through 2026, then 6% a year from year-end 2026 through 2028.
The Dominion Energy deal is still in play. On Nov. 6, Virginia regulators’ staff recommended against approving it as structured, even after the companies agreed to 101 of 117 proposed conditions. None of that touches today’s dividend, but the combined company’s 9%+ EPS growth target rests on the deal.
The main risk is debt: net debt is 8.1x EBITDA, and management expects to need about $12 billion to $17 billion of new equity through 2032.
So which one would I hold?
My pick for the next 10 years is Pfizer. At each dividend’s 5-year rate, $10,000 in Pfizer pays about $6,835 over the decade, against about $4,815 from NextEra, about $2,020 more. NextEra’s income wouldn’t pass Pfizer’s until about 2036, and that’s with 10.1% raises every year, faster than the 6% NextEra guides to through 2028.
Pfizer doesn’t even need another raise to come out ahead over those 10 years. It needs to keep paying. The main threat to that is revenue, which analysts expect to shrink through 2028:

Consensus has fiscal 2028 revenue at $55.4 billion, against $62.6 billion in fiscal 2025. Still, Pfizer expects to deliver nearly all of $7.2 billion in net cost savings by the end of 2026, then $2.5 billion more from 2027 to 2029. That gives it room to keep the check intact.
NextEra’s dividend has the wider cushion and the faster growth. In year 10, its check would be about $716, a 7.2% yield on today’s $10,000, close to Pfizer’s $762. Its stock could also do more of the work, if that growth plan comes through. But over a 10-year hold, Pfizer’s head start in income is worth more to me than NextEra’s cushion.
Of course, Pfizer hasn’t given 2027 guidance yet. CFO Cecile Guegan said it will reflect two of Pfizer’s products entering Medicare’s negotiated prices in 2027. If that guidance leaves free cash flow well short of the dividend, I’d revisit this pick.
Forget Pfizer: 6 safe 6%+ dividend yields you can buy right now
Dividends can hold the key to enormous wealth. But only if you buy the right ones.
Picking the right high-yield dividend stock can be the difference between a dream retirement…and scraping by every month, waiting for the next Social Security check to clear.
We’ve identified six stocks yielding 6%+ that we believe every retiree should know about right now. (And Pfizer isn’t one of them.)
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!